September 26, 2018 / 10:43 AM / 23 days ago

Alexion to buy biotech firm Syntimmune for up to $1.2 bln

Sept 26 (Reuters) - Alexion Pharmaceuticals Inc said on Wednesday it would buy privately held biotech company Syntimmune for a total value of up to $1.2 billion, giving it access to a rare blood disorder drug.

Alexion said it would make an upfront payment of $400 million and additional milestone-dependent payments of up to $800 million. (Reporting by Saumya Sibi Joseph in Bengaluru; Editing by Anil D’Silva)

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below